department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Crenessity · pharmadog

pharmadog
drugs
Crenessity

drug

patient view →

crinecerfont

Marketedupdated 2mo ago

by $NBIX NEUROCRINE BIOSCIENCES INC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Crenessity

generic

crinecerfont

indication

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 13, 2029

~3.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

Jun 9, 2041compositionUS 12128033
Jun 9, 2041compositionUS 12128033
Jun 9, 2041compositionUS 12128033
Jun 9, 2041compositionUS 12128033
Jan 21, 2035method-of-use (U-4049)US 10905690
Jan 21, 2035method-of-use (U-4049)US 10905690
Jan 21, 2035method-of-use (U-4049)US 10905690
Jan 21, 2035method-of-use (U-4049)US 10905690
Jan 21, 2035method-of-use (U-4049)US 11311544
Jan 21, 2035method-of-use (U-4049)US 11311544
Jan 21, 2035method-of-use (U-4049)US 11311544
Jan 21, 2035method-of-use (U-4049)US 11311544
Jan 21, 2035method-of-use (U-4049)US 11730739
Jan 21, 2035method-of-use (U-4049)US 11730739
Jan 21, 2035method-of-use (U-4049)US 11730739
Jan 21, 2035method-of-use (U-4049)US 11730739

FDA exclusivities (8)

Dec 13, 2031ODE-503Orphan Drug (7y)
Dec 13, 2031ODE-503Orphan Drug (7y)
Dec 13, 2031ODE-503Orphan Drug (7y)
Dec 13, 2031ODE-503Orphan Drug (7y)
Dec 13, 2029NCENew Chemical Entity (5y)3.4y
Dec 13, 2029NCENew Chemical Entity (5y)3.4y
Dec 13, 2029NCENew Chemical Entity (5y)

3.4y

Dec 13, 2029NCENew Chemical Entity (5y)3.4y

Trials studying crinecerfont

phase2Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Oldactive not recruitingn=7
phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Oldnot yet recruitingn=20
phase3Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)active not recruitingn=103
phase3Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasiaactive not recruitingn=182
phase2Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasiacompletedn=8